Kidney Transplantation in Multiple Myeloma and Monoclonal Gammopathy of Renal Significance

Leung N., HEYBELİ C.

Seminars in Nephrology, 2024 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Review
  • Publication Date: 2024
  • Doi Number: 10.1016/j.semnephrol.2024.151497
  • Journal Name: Seminars in Nephrology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, CINAHL, Veterinary Science Database
  • Keywords: Kidney transplantation, multiple myeloma, paraproteinemia, recurrence, relapse
  • Dokuz Eylül University Affiliated: Yes


Recent advances in the treatment of plasma cell disorders (PCDs) have provided a wealth of therapy alternatives and improved overall survival tremendously. Various types of PCDs are associated with kidney injury and end-stage kidney disease in a considerable number of patients. Kidney transplantation (KTx) is the best option for renal replacement therapy in select patients in terms of both quality of life parameters and overall survival. Even with modern therapies, all PCDs carry the risk of hematologic progression, whereas histologic recurrence and graft loss are other prevailing concerns in these patients. The risk of mortality is also higher in some of these disorders compared with KTx recipients who suffer from other causes of kidney disease. Unlike solid cancers, there is no well-defined “waiting time” after hematologic remission before proceeding to KTx. Thus, clinicians are usually reluctant to recommend KTx to patients who develop end-stage kidney disease due to PCDs. This review aims to provide the current evidence on KTx outcomes in patients with monoclonal gammopathy of renal significance and multiple myeloma. Although immunoglobulin light chain amyloidosis is a monoclonal gammopathy of renal significance subtype, KTx outcomes in this group are mentioned in another chapter of this issue.